- Home
- BZAI vs UNCY Comparison
BZAI vs UNCY Comparison
Compare BZAI & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BZAI | UNCY |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | 232 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.0M | 145.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BZAI | UNCY |
|---|---|---|
| Price | $1.10 | $6.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.50 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 1.8M | 432.4K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | $2,317.12 | N/A |
| Revenue Next Year | $250.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.45 |
| 52 Week High | $6.76 | $7.57 |
Technical Indicators
Market Signals| Indicator | BZAI | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 50.35 |
| Support Level | $1.04 | $6.48 |
| Resistance Level | $1.57 | $6.82 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 45.45 | 39.60 |
Price Performance
Historical ComparisonAbout BZAI Blaize Holdings Inc.
Blaize Holdings Inc provides a customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.